Form 4: Pasithea Therapeutics CFO Acquires Stock Options

Daniel Schneiderman, CFO of Pasithea Therapeutics, reports acquisition of stock options in the company.

Summary

• Daniel Schneiderman, the Chief Financial Officer of Pasithea Therapeutics Corp., filed a Form 4 on March 1, 2024, reporting changes in beneficial ownership.
• Schneiderman acquired two stock option grants on March 1, 2024.
• The first grant is for 10,000 shares, vesting over three years, with 33% vesting after one year and the remainder in equal quarterly installments.
• The second grant is for 5,927 shares, fully vested upon issuance and exercisable on March 1, 2024.
• Both options have an exercise price of $8.34 and expire on February 28, 2034.
• The awards were made under the company's 2023 Stock Incentive Plan.
• A 1-for-20 reverse stock split was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The grants align management with shareholders, which is a slight positive.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule of one option encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Vesting schedules, like the one described (33% after one year, then quarterly), are standard practice to incentivize long-term performance.
• The size of the grant (10,000 and 5,927 shares) would need to be compared to grants given to CFOs at similarly sized biotech companies to assess its relative value.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the CFO to work towards increasing shareholder value.

Key Dates

Keywords

stock options, Form 4, Daniel Schneiderman, Pasithea Therapeutics, KTTA, CFO, beneficial ownership, reverse stock split, equity awards, 2023 Stock Incentive Plan